|
rs4919510
|
|
Primary malignant neoplasm of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
The individuals with both risk genotypes of miRNA SNPs and exposure to risk factor (cooking oil fumes) were in a higher risk of lung cancer than persons with only one of the two risk factors (ORs were 1.91, 1.05 and 1.41 for miR-146a rs2910164, ORs were 1.94, 1.23 and 1.34 for miR-196a2 rs11614913, ORs were 2.06, 1.41 and 1.68 for miR-608 rs4919510, ORs were 1.76, 0.82 and 1.07 for miR-27a rs895819, and ORs were 2.13, 1.15 and 1.02 for miR-423 rs6505162, respectively).
|
26083623 |
2015 |
|
rs4919510
|
|
Malignant neoplasm of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
The individuals with both risk genotypes of miRNA SNPs and exposure to risk factor (cooking oil fumes) were in a higher risk of lung cancer than persons with only one of the two risk factors (ORs were 1.91, 1.05 and 1.41 for miR-146a rs2910164, ORs were 1.94, 1.23 and 1.34 for miR-196a2 rs11614913, ORs were 2.06, 1.41 and 1.68 for miR-608 rs4919510, ORs were 1.76, 0.82 and 1.07 for miR-27a rs895819, and ORs were 2.13, 1.15 and 1.02 for miR-423 rs6505162, respectively).
|
26083623 |
2015 |
|
rs4919510
|
|
Colorectal Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
There was no significant association between rs4919510 and colorectal cancer risk (African American: OR(GG vs. CC) 0.89 [95% CI, 0.41-1.80]) (Caucasian: OR(GG vs. CC) 1.76, ([95% CI, 0.48-6.39]).
|
22606253 |
2012 |
|
rs4919510
|
|
Breast Carcinoma
|
|
0.050 |
GeneticVariation
|
BEFREE |
In the first set, although rs4919510:C>G was unrelated to breast cancer in general patients, variant genotypes (CG/GG) were specifically associated with increased risk of HER2-positive subtype (Adjusted OR = 1.97, 95% CI, 1.34-2.90 in the recessive model).
|
22586447 |
2012 |
|
rs4919510
|
|
Malignant neoplasm of breast
|
|
0.050 |
GeneticVariation
|
BEFREE |
In the first set, although rs4919510:C>G was unrelated to breast cancer in general patients, variant genotypes (CG/GG) were specifically associated with increased risk of HER2-positive subtype (Adjusted OR = 1.97, 95% CI, 1.34-2.90 in the recessive model).
|
22586447 |
2012 |
|
rs4919510
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, the prognosis of rs4919510 variant in cancer patients showed that rs4919510 GG genotype was significant association with poor recurrence-free survival in homozygous models (<i>P</i> = 0.04).
|
29909406 |
2018 |
|
rs4919510
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, the prognosis of rs4919510 variant in cancer patients showed that rs4919510 GG genotype was significant association with poor recurrence-free survival in homozygous models (<i>P</i> = 0.04).
|
29909406 |
2018 |
|
rs4919510
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
It was shown that 6 miRNAs SNPs (miR-608 rs4919510, miR-492 rs2289030, miR-378 rs1076064, miR-499 rs4919510, miR-149 rs2292832, miR-196a2 rs11614913) were associated with better cancer overall survival (OS) while let-7i rs10877887 was associated with poor OS; the homozygous and heterozygote genotype of miR-423 were related to poor cancer relapse-free survival (RFS) when compared with the wild genotype; miR-146 rs2910164 was linked to favorable cancer DFS while miR-196a2 rs11614913 was associated with poor DFS.
|
30619739 |
2018 |
|
rs4919510
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
It was shown that 6 miRNAs SNPs (miR-608 rs4919510, miR-492 rs2289030, miR-378 rs1076064, miR-499 rs4919510, miR-149 rs2292832, miR-196a2 rs11614913) were associated with better cancer overall survival (OS) while let-7i rs10877887 was associated with poor OS; the homozygous and heterozygote genotype of miR-423 were related to poor cancer relapse-free survival (RFS) when compared with the wild genotype; miR-146 rs2910164 was linked to favorable cancer DFS while miR-196a2 rs11614913 was associated with poor DFS.
|
30619739 |
2018 |
|
rs4919510
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
By further stratified analysis, we found that rs4919510 SNP had some relationship with decreased c</span>ancer risk in both homozygote model (CC vs. GG: OR=0.59, 95% CI: 0.36-0.96, P=0.034) and dominant model (CG+ CC vs. GG: OR=0.60, 95% CI: 0.37-0.98, P=0.042) in Caucasians but no relationship in any genetic model in Asians.
|
27223084 |
2017 |
|
rs4919510
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
By further stratified analysis, we found that rs4919510 SNP had some relationship with decreased c</span>ancer risk in both homozygote model (CC vs. GG: OR=0.59, 95% CI: 0.36-0.96, P=0.034) and dominant model (CG+ CC vs. GG: OR=0.60, 95% CI: 0.37-0.98, P=0.042) in Caucasians but no relationship in any genetic model in Asians.
|
27223084 |
2017 |
|
rs4919510
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
These findings provide evidence that the miR-608 rs4919510 polymorphism may modify cancer susceptibility in a type-specific manner.
|
28653886 |
2017 |
|
rs4919510
|
|
Malignant Neoplasms
|
|
0.040 |
GeneticVariation
|
BEFREE |
These findings provide evidence that the miR-608 rs4919510 polymorphism may modify cancer susceptibility in a type-specific manner.
|
28653886 |
2017 |
|
rs4919510
|
|
Papillary thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
When stratifying by different cancer sites, rs4919510 polymorphism was detected to have a significant association with a decreased risk of colorectal cancer in homozygous model (<i>P</i> = 0.006) and recessive model (<i>P</i> = 0.001), subgroup analysis also emerged a weakened correlation between rs4919510 polymorphism and an increased risk of papillary thyroid cancer in heterozygote model (<i>P</i> = 0.04).
|
29909406 |
2018 |
|
rs4919510
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
The meta-analysis suggested that the microRNA-608 rs4919510 polymorphism maybe associate with a significantly decreased risk for colorectal cancer.
|
29909406 |
2018 |
|
rs4919510
|
|
Papillary thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
In further stratified analyses based on cancer type, rs4919510 was significantly associated with an increased risk of papillary thyroid cancer (CG vs CC: odds ratio = 1.25; 95% confidence interval = 1.01-1.54) and exhibited borderline significant associations with increased risk of gastric cancer (GG vs CC: odds ratio = 1.27; 95% confidence interval = 1.00-1.62) and lung cancer (CG vs CC: odds ratio = 1.14; 95% confidence interval = 0.99-1.32), but a decreased risk of colorectal cancer (GG vs CC: odds ratio = 0.74; 95% confidence interval = 0.60-0.91).
|
28653886 |
2017 |
|
rs4919510
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
Moreover, the RegulomeDB database indicated that rs4919510 may affect the expression of two nearby genes ( SEMA4G and MRPL43), and the Cancer Genome Atlas database revealed that the expression level of SEMA4G was significantly lower in colorectal cancer and lung cancer tissues than that in adjacent non-tumour tissues, while the expression level of SEMA4G was significantly higher in gastric cancer tissues than that in adjacent non-tumour tissues.
|
28653886 |
2017 |
|
rs4919510
|
|
Papillary thyroid carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Three SNPs (rs67106263 in mir-3144, GA versus GG, OR = 1.35, 1.09-1.68; rs4919510 in mir-608, CC versus GG/GC, OR = 0.76, 0.60-0.97; and rs79402775 in mir-933, AA versus GG/GA, OR = 1.76, 1.00-3.12) were associated with PTC risk.
|
25381599 |
2015 |
|
rs4919510
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.030 |
GeneticVariation
|
BEFREE |
There was no significant association between rs4919510 and colorectal cancer risk (African American: OR(GG vs. CC) 0.89 [95% CI, 0.41-1.80]) (Caucasian: OR(GG vs. CC) 1.76, ([95% CI, 0.48-6.39]).
|
22606253 |
2012 |
|
rs4919510
|
|
Head and Neck Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
By further stratified analysis, we found that rs4919510 mutation contributed to the risk of HNC amongst Asians under homozygote model (<i>I</i><sup>2</sup> =0, <i>P</i><sub>heterogeneity</sub>=0.541, OR =1.189, 95% CI =1.025-1.378, <i>P</i>=0.022), and dominant model (<i>I</i><sup>2</sup> =0, <i>P</i><sub>heterogeneity</sub>=0.959, OR =1.155, 95% CI =1.016-1.312, <i>P</i>=0.028).
|
29208766 |
2018 |
|
rs4919510
|
|
Malignant Head and Neck Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
By further stratified analysis, we found that rs4919510 mutation contributed to the risk of HNC amongst Asians under homozygote model (<i>I</i><sup>2</sup> =0, <i>P</i><sub>heterogeneity</sub>=0.541, OR =1.189, 95% CI =1.025-1.378, <i>P</i>=0.022), and dominant model (<i>I</i><sup>2</sup> =0, <i>P</i><sub>heterogeneity</sub>=0.959, OR =1.155, 95% CI =1.016-1.312, <i>P</i>=0.028).
|
29208766 |
2018 |
|
rs4919510
|
|
Head and Neck Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our analysis revealed that HOTAIR rs920778, uc003opf.1 rs11752942, and miR-196a2 rs11614913 were related to HNC susceptibility, while let-7 rs10877887, miR-124-1rs531564, and miR-608 rs4919510 were considered as protective factors.
|
28977965 |
2017 |
|
rs4919510
|
|
Malignant Head and Neck Neoplasm
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our analysis revealed that HOTAIR rs920778, uc003opf.1 rs11752942, and miR-196a2 rs11614913 were related to HNC susceptibility, while let-7 rs10877887, miR-124-1rs531564, and miR-608 rs4919510 were considered as protective factors.
|
28977965 |
2017 |
|
rs4919510
|
|
Liver carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
In conclusion, our results illustrated the potential role of miR-608 rs4919510 as a prognostic marker for HCC patients undergoing surgical resection of the tumor.
|
26815502 |
2016 |
|
rs4919510
|
|
Neoplasms
|
|
0.020 |
GeneticVariation
|
BEFREE |
Further stratification analysis indicated that rs4919510 was significantly associated with OS in patients who were satisfied with one of the following criteria: male gender, HbsAg-positive, α-fetoprotein (AFP)-positive, tumor size >5 cm, cirrhosis, solitary tumor, I + II pTNM stage, or no tumor capsule.
|
26815502 |
2016 |